Crestor Pre-Surgery Hold Window: What You Need to Know About Rosuvastatin Before an Operation

Why Surgeons and Cardiologists Rarely Stop Rosuvastatin Before an Operation

The short answer is that stopping rosuvastatin before surgery almost always causes more harm than leaving it in place. Multiple prospective cohorts and the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation (updated 2022) place statin continuation at a Class I, Level of Evidence B recommendation for patients undergoing non-cardiac surgery who are already receiving statin therapy. The ACC/AHA 2022 Guideline states: "Statins should be continued in patients currently taking statins who are scheduled for noncardiac surgery."

Rosuvastatin is a fully synthetic, high-intensity statin with an approximate plasma half-life of 19 hours, but its tissue residence is considerably longer. That pharmacokinetic profile means even a 2-day hold removes measurable pleiotropic benefit, including endothelial stabilization, anti-inflammatory signaling, and platelet modulation.

The Rebound Phenomenon After Statin Withdrawal

When statin therapy is stopped abruptly, hsCRP and IL-6 can rise within 72 hours in patients with established atherosclerosis. A 2009 analysis published in the Journal of the American College of Cardiology found that abrupt statin withdrawal in patients hospitalized with acute coronary syndromes was associated with a more than two-fold increase in 30-day mortality compared with continued therapy (Heeschen et al., JACC 2002).

This rebound is not purely theoretical. Rho-kinase pathway upregulation returns within days of discontinuation, re-activating the very inflammatory cascades that statins suppress. For a patient already under surgical stress, that simultaneous inflammatory surge represents a real risk.

What "Hold Window" Actually Means in Clinical Practice

The phrase "hold window" describes the interval between the last dose taken and the surgical incision. A 5-to-7-day window is sometimes cited for elective procedures where there is a specific pharmacokinetic reason to clear the drug (for example, avoiding drug-drug interactions with anesthetics that are metabolized by pathways affected by rosuvastatin's OATP1B1 transporter interactions). In practice, those scenarios are uncommon. For the vast majority of elective surgeries, including major abdominal, orthopedic, and cardiac procedures, no hold is indicated.

JUPITER Trial: The Foundational Evidence for Rosuvastatin's Cardiovascular Benefit

The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) enrolled 17,802 apparently healthy adults with LDL below 130 mg/dL but elevated hsCRP of 2.0 mg/L or higher (Ridker et al., NEJM 2008). Participants were randomized to rosuvastatin 20 mg daily or placebo.

Key Efficacy Findings

At a median follow-up of 1.9 years, the rosuvastatin group showed a 44% reduction in the composite primary endpoint of major cardiovascular events (MI, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death), with a hazard ratio of 0.56 (95% CI 0.46 to 0.69, P<0.00001) (Ridker et al., NEJM 2008). All-cause mortality fell 20%, and the trial was stopped early by the independent data safety and monitoring board because the benefit was so clear.

For perioperative context, JUPITER's data matter because they define the patient population most likely to be taking rosuvastatin: middle-aged to older adults with controlled LDL but residual inflammatory risk. These patients are precisely the ones scheduled for elective procedures, and their benefit from continued therapy is well-documented.

hsCRP Reduction and Surgical Stress

JUPITER demonstrated a 37% reduction in hsCRP on rosuvastatin 20 mg versus placebo at 12 months (Ridker et al., NEJM 2008). Surgical trauma generates a systemic inflammatory response. Preserving statin-mediated hsCRP suppression through the perioperative period may blunt the magnitude of that response, particularly in patients undergoing vascular reconstruction or open cardiac procedures.

ACC/AHA and ESC Guideline Positions on Perioperative Statin Use

ACC/AHA 2022 Perioperative Guideline

The 2022 ACC/AHA Guideline on Perioperative Cardiovascular Management for Noncardiac Surgery gives a Class I recommendation to continue statin therapy perioperatively in patients already taking it (Fleisher et al., AHA Journals 2022). For patients undergoing vascular surgery who are not yet on a statin but have clinical indications, initiation before surgery receives a Class IIa recommendation.

The guideline explicitly notes that statin withdrawal is associated with increased perioperative myocardial injury, and it does not endorse routine preoperative discontinuation for any surgical category.

ESC 2022 Cardiovascular Assessment Guidelines

The European Society of Cardiology's 2022 guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery likewise state that statins should be maintained perioperatively in all patients with established cardiovascular disease or high cardiovascular risk (ESC 2022, European Heart Journal). The ESC further specifies that for major vascular surgery, statin therapy ideally should be started at least 2 weeks before the procedure in statin-naive patients to allow pleiotropic effects to develop.

Where a Hold Might Be Considered

No major society currently recommends routine statin discontinuation before surgery. A hold may be considered in two narrow situations. First, if a severe drug-drug interaction arises perioperatively: for example, a patient starting cyclosporine post-transplant, since cyclosporine raises rosuvastatin AUC approximately 7-fold, requiring dose reduction rather than discontinuation (FDA rosuvastatin prescribing information). Second, if a patient develops rhabdomyolysis or severe hepatotoxicity in the immediate perioperative window, though this is rare.

Rosuvastatin Pharmacokinetics Relevant to the Perioperative Setting

Half-Life, Absorption, and Tissue Distribution

Rosuvastatin has a plasma half-life of approximately 19 hours, reaching steady-state plasma concentrations in about 4 days with once-daily dosing. Its oral bioavailability is roughly 20%, lower than atorvastatin's 14% but higher than most other hydrophilic statins. Unlike lipophilic statins such as simvastatin or lovastatin, rosuvastatin does not cross the blood-brain barrier to a significant degree and is not extensively metabolized by CYP3A4 (FDA rosuvastatin prescribing information).

This CYP3A4 independence is clinically relevant in surgery, because many anesthetic agents are CYP3A4 substrates or inhibitors. Rosuvastatin's primary metabolic pathway involves CYP2C9 (minor) and OATP1B1/1B3 hepatic transporters, so it has a lower pharmacokinetic interaction burden with common general anesthetics than simvastatin does.

NPO Status and Morning-of-Surgery Dosing

A common question from patients: can you take rosuvastatin the morning of surgery with a sip of water during NPO (nothing by mouth) fasting? Most anesthesiologists permit oral medications with a small amount (15 to 30 mL) of water even during NPO protocols. The 2017 American Society of Anesthesiologists (ASA) Practice Guidelines on preoperative fasting do not categorize oral medications with sips of water as a fasting violation (ASA 2017, Anesthesiology). Patients on rosuvastatin should take their dose the morning of surgery unless the surgical team or anesthesiologist instructs otherwise.

Post-Operative Restart

Once a patient tolerates oral fluids, rosuvastatin should restart within 24 hours. If enteral access is not available and the patient has high cardiovascular risk (prior MI, unstable angina, or recent coronary revascularization), intravenous statin formulations are not commercially available in the United States, but some institutions use nasogastric administration of crushed tablets when clinically warranted. Crushing rosuvastatin tablets is generally acceptable since they are not extended-release formulations, though this should be confirmed with pharmacy for the specific product.

Perioperative Statin Continuation: Evidence Beyond JUPITER

The DECREASE and Dutch Echocardiographic Cardiac Risk (DECREASE III) Trial

DECREASE III randomized 497 patients undergoing major vascular surgery to fluvastatin XL 80 mg versus placebo, starting at least 37 days before surgery (Schouten et al., Lancet 2009). Perioperative myocardial ischemia occurred in 10.8% of the fluvastatin group versus 19.0% in placebo (hazard ratio 0.55, 95% CI 0.34 to 0.88, P=0.01). While fluvastatin is not rosuvastatin, the pleiotropic class effect on endothelial function and platelet aggregation applies broadly, and the data support the concept of continuation rather than withdrawal.

Observational Data on Statin Withdrawal and Surgical Mortality

A retrospective cohort of 15,220 patients undergoing noncardiac surgery published in Circulation found that patients who had their statin discontinued within 4 days of surgery had a significantly higher rate of in-hospital cardiovascular complications (OR 1.94, 95% CI 1.61 to 2.32) compared with those whose therapy was maintained (Le Manach et al., Circulation 2007). That figure translates to a near-doubling of cardiovascular event risk from what is, for most patients, an unnecessary drug hold.

Rosuvastatin-Specific Data in Cardiac Surgery

A prospective randomized trial by Chello et al. Evaluated rosuvastatin 20 mg daily started 7 days before elective coronary artery bypass grafting (N=80) versus placebo. Rosuvastatin-treated patients had lower post-operative CRP levels (5.8 vs. 8.7 mg/L, P<0.05), lower rates of postoperative atrial fibrillation (15% vs. 32.5%, P<0.05), and shorter ICU stays (Chello et al., Annals of Thoracic Surgery 2006). Postoperative atrial fibrillation is one of the most common complications of cardiac surgery, and statin pretreatment appears to reduce it meaningfully.

Special Populations and Surgical Scenarios

Vascular Surgery Patients

This group has the highest absolute cardiovascular risk at baseline and the strongest evidence for perioperative statin benefit. The ACC/AHA Class IIa recommendation to initiate statins in statin-naive vascular surgery patients (not just continue them) underlines how important the drug class is in this context (Fleisher et al., AHA Journals 2022). For a patient already on rosuvastatin, stopping it before vascular surgery is contraindicated in the absence of a specific safety concern.

Cardiac Surgery and Cardiopulmonary Bypass

Cardiopulmonary bypass generates a massive systemic inflammatory response. Rosuvastatin's hsCRP-lowering and pleiotropic effects provide a theoretical and clinically observed benefit in this setting, as supported by the Chello trial data above. Pre-operative loading with rosuvastatin 20 mg for 7 days is practiced at many centers for elective CABG, though it is not yet a uniform guideline recommendation.

Orthopedic and Spinal Surgery

For elective hip arthroplasty, knee replacement, or spinal fusion, no evidence supports stopping rosuvastatin. The surgical team may be concerned about bleeding, but statins do not meaningfully affect hemostasis through platelet inhibition in the way that antiplatelet agents do. The primary perioperative concern with statins in orthopedic surgery is myopathy in the context of aggressive post-operative pain management with medications that interact with OATP1B1, but this is a monitoring issue, not a reason to discontinue pre-operatively.

Patients With CKD

Rosuvastatin is largely excreted unchanged in feces (approximately 90%) and does not require dose adjustment for mild-to-moderate renal impairment. For patients with severe CKD (eGFR <30 mL/min/1.73 m2), the FDA recommends a maximum dose of 10 mg/day, and this dose limit applies perioperatively as well (FDA rosuvastatin prescribing information). Perioperative acute kidney injury is a real concern in major surgery, and the team should track eGFR and adjust dose at restart if kidney function has changed.

Practical Decision Framework for Rosuvastatin Around Surgery

The following framework reflects current guideline positions and the clinical evidence reviewed above. It is intended for use by clinicians managing patients on rosuvastatin who are preparing for elective or semi-urgent procedures.

Step 1. Confirm indication and dose. Document whether the patient is on rosuvastatin for primary prevention (JUPITER profile: normal LDL, elevated hsCRP), secondary prevention (established ASCVD), or familial hypercholesterolemia. Doses range from 5 mg to 40 mg daily; the maximum approved U.S. Dose is 40 mg/day (FDA rosuvastatin prescribing information).

Step 2. Assess surgical category. Categorize the procedure as low, intermediate, or high cardiac risk per ACC/AHA definitions. High-risk procedures include major vascular surgery, open thoracic surgery, and major abdominal operations expected to last more than 3 hours.

Step 3. Default is continuation. For all categories, the default decision is to continue rosuvastatin at the current dose. The morning-of-surgery dose should be taken with 15 to 30 mL of water per standard ASA fasting guidance.

Step 4. Identify narrow exceptions. Hold rosuvastatin only if a serious drug-drug interaction is newly introduced perioperatively (cyclosporine, certain antiretroviral combinations), or if the patient develops active myopathy or hepatitis during the admission. A formulaic 5-to-7-day pre-operative hold is not supported by current evidence and should not be applied as routine policy.

Step 5. Plan the restart. Document in the surgical orders that rosuvastatin should restart within 24 hours of tolerating oral intake. Include dose verification to account for any new medications started post-operatively that could alter rosuvastatin exposure.

Monitoring Parameters Perioperatively

Clinicians managing patients on rosuvastatin through surgery should track three lab values: creatine kinase (CK) if myalgia develops post-operatively, liver enzymes (AST/ALT) if hepatotoxic drugs are added, and creatinine/eGFR to guide dose adjustment in patients who develop AKI.

Routine pre-operative CK measurement is not required in asymptomatic patients (ACC/AHA statin safety guidelines, JACC 2019). The ACC/AHA 2019 statin safety statement notes that baseline CK is warranted only in patients at elevated risk for muscle disease, such as those with prior statin intolerance, personal or family history of myopathy, or planned high-intensity exercise regimens.

Rosuvastatin 40 mg carries a higher myopathy risk than lower doses, particularly in Asian patients, where the FDA labeling recommends a starting dose of 5 mg and a maximum of 20 mg due to approximately 2-fold higher AUC compared with Caucasian patients (FDA rosuvastatin prescribing information). This pharmacogenomic difference should be considered when evaluating post-operative myalgia in Asian surgical patients.